() said discussions to form a joint venture with investment firm Alpha Blue Ocean have not progressed beyond what it told the market in May and June.
As a result, any deal brokered “will be considered along with other opportunities”.
The update came as the drug developer said Novum was its new nominated adviser after SVS Securities was placed into administration.
ValiRx said it expects to receive a £400,000 R&D tax credit shortly. In the meantime, it continues to carefully manage its working capital position.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of ValiRx PLC named herein, including the promotion by the Company of ValiRx PLC in any Content on the Site, the Company receives from said issuer...
FOR OUR FULL DISCLAIMER CLICK HERE